Pharmacovigilance and global HIV/AIDS

Current Opinion in HIV and AIDS

Volumn 7, Issue 4, 2012, Pages 299-304

  Miller, Veronica ^a   Nwokike, Jude ^b   Stergachis, Andy ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MANAGEMENT SCIENCES FOR HEALTH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

drug toxicities; fixed dose combination generic antiretrovirals; observational cohorts; pharmacovigilance; randomized clinical trials

Indexed keywords

ANTIRETROVIRUS AGENT; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CREATININE CLEARANCE; DIARRHEA; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALNUTRITION; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG TOXICITY; HEALTH POLICY; HIV INFECTIONS; HUMANS; PHARMACOVIGILANCE; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; WORLD HEALTH;

EID: 84862563635     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328354d8e7     Document Type: Review

References (35)

1. Bisson G, Gross R, Miller V, et al. Monitoring of long-term toxicities of HIV treatments: an international perspective. AIDS 2003; 17:2407-2417. (Pubitemid 38393312)
2. Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low and middle-income countries: a questionnaire-based analysis. Drug Saf 2010; 33:689-703.
3. UNGASS. Declaration of Commitment on HIV/AIDS. 2001. Available from data.unaids.org/publications/irc-pub03/aidsdeclaration-en.pdf. [Accessed May 2012]
4. UNAIDS. Getting to Zero. World AIDS Day Report. 2011. Available from www.unaids.org. [Accessed May 2012]
5. FDA. Presidents Emergency Plan for AIDS Relief: approved and tentatively approved antiretrovirals in association with the Presidents Emergency Plan. Available at http://www.fda.gov/InternationalPrograms/FDABeyond OurBordersForeignOffices/AsiaandAfrica/ucm119231.htm. [Accessed May 2012]
6. Stergachis A, Bartlein RJ, Dodoo A, et al. A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. Presidents Malaria Initiative proposals. Malar J 2010; 9:148.
7. The Global Fund. An analysis of grant applications in the Global Fund database of the extent of their inclusion of pharmacovigilance activities. In: Proceedings of the Executive summary presented during WHO-Global Fund Stakeholders Meeting in Pharmacovigilance; 2010; Accra, Ghana.
8. Bakare N, Edwards IR, Stergachis A, et al. Global pharmacovigilance for antiretroviral drugs: overcoming contrasting priorities. PLoS Med 2011; 8:e1001054.
9. FDA. Draft guidance for industry: postmarketing safety reporting for human drug and biologic products including vaccines. 2001. Available from http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegu latoryInformation/Guidances/Vaccines/ucm074850.htm. [Accessed May 2012]
10. European Union. Legislation: Guidelines of pharmacovigilance for medicinal products for human and veterinary use. Available at http://ec.europa.eu/ health/human-use/pharmacovigilance/index-en.htm#geninf. [Accessed May 2012]
11. MHRA. Good Pharmacovigilance Practice. Available at http://www.mhra.gov. uk/Howweregulate/Medicines/Inspectionandstandards/GoodPharmacovigil ancePractice/index.htm. 2012. [Accessed May 2012]
12. Kigen G, Kimaiyo S, Nyandiko W, et al. Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort. PLoS One 2011; 6:e16800.
13. Mehta U, Durrheim DN, Blockman M, et al. Adverse drug reactions in adult medical inpatients in a south African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol 2008; 65:396-406. (Pubitemid 351320492)
14. Ssali F, Stohr W, Munderi P, et al. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther 2006; 11:741-749. (Pubitemid 44497169)
15. Haas DW, Kuritzkes DR, Ritchie MD, et al. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials 2011; 12:277-285.
16. Lubomirov R, Colombo S, di Iulio J, et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis 2011; 203:246-257.
17. Vanasse GJ, Jeong JY, Tate J, et al. A polymorphism in the leptin gene promoter is associated with anemia in patients with HIV disease. Blood 2011; 118:5401-5408.
18. Boulle A, Orrel C, Kaplan R, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large south African cohort. Antivir Ther 2007; 12:753-760. (Pubitemid 47235489)
19. Geng EH, Hunt PW, Diero LO, et al. Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. J Int AIDS Soc 2011; 14:46.
20. Davies MA, Meintjes G. Assessing the contribution of the immune reconstitution inflammatory syndrome to mortality in developing country antiretroviral therapy programs. Clin Infect Dis 2009; 49:973-975.
21. World Health Organization. Survey of the quality of antiretroviral medicines circulating in selected african countries. Available at http://www.who.int/ medicines/publications/ARV-survey.pdf 2007. [Accessed May 2012]
22. Pirmohamed M, Atuah KN, Dodoo AN, Winstanley P. Pharmacovigilance in developing countries. BMJ 2007; 335:462. (Pubitemid 47401595)
23. Jaquet A, Djima MM, Coffie P, et al. Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote dIvoire. Pharmacoepidemiol Drug Saf 2011; 20:1303-1310.
24. Bygrave H, Kranzer K, Hilderbrand K, et al. Renal safety of a tenofovircontaining first line regimen: experience from an antiretroviral cohort in rural Lesotho. PLoS One 2011; 6:e17609.
25. Jouquet G, Bygrave H, Kranzer K, et al. Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho. J Acquir Immune Defic Syndr 2011; 58:e68-e74.
26. Corbell C, Katjitae I, Mengistu A, et al. Records linkage of electronic databases for the assessment of adverse effects of antiretroviral therapy in sub-Saharan Africa. Pharmacoepidemiol Drug Saf 2011. Published online in Wiley Online Library (wileyonlinelibrary.com) doi: 10.1002/pds.2252.
27. Braitstein P, Einterz RM, Sidle JE, et al. Talkin about a revolution: How electronic health records can facilitate the scale-up of HIV care and treatment and catalyze primary care in resource-constrained settings. J Acquir Immune Defic Syndr 2009; (52 SUPPL. 1):S54-S57.
28. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral, therapy in Africa (DART): a randomized noninferiority trial. Lancet 2010; 375:121-131.
29. Ndembi N, Goodall RL, Dunn DT, et al. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis 2010; 201:106-113.
30. Muyingo SK, Walker AS, Reid A, et al. Patterns of individual and populationlevel adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr 2008; 48:468-475.
31. Lyagoba F, Dunn DT, Pillay D, et al. Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring. J Acquir Immune Defic Syndr 2010; 55:277-283.
32. McCormick AL, Goodall RL, Joyce A, et al. Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/ zidovudine and lamivudine in a resource-limited setting. J Acquir Immune Defic Syndr 2010; 54:215-216.
33. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
34. DeGruttola V, Smith DM, Little SJ, Miller V. Developing and evaluating comprehensive HIV infection control strategies: issues and challenges. Clin Infect Dis 2010; 50 (SUPPL. 3):S102-S107.
35. Curran K, Baeten JM, Coates TJ, et al. HIV-1 prevention for HIV-1 serodiscordant couples. Curr HIV/AIDS Rep 2012. [Epub ahead of print]